全文获取类型
收费全文 | 65106篇 |
免费 | 7126篇 |
国内免费 | 2414篇 |
专业分类
耳鼻咽喉 | 148篇 |
儿科学 | 592篇 |
妇产科学 | 277篇 |
基础医学 | 2636篇 |
口腔科学 | 428篇 |
临床医学 | 5596篇 |
内科学 | 7463篇 |
皮肤病学 | 1179篇 |
神经病学 | 2116篇 |
特种医学 | 674篇 |
外国民族医学 | 10篇 |
外科学 | 1967篇 |
综合类 | 8839篇 |
现状与发展 | 6篇 |
一般理论 | 3篇 |
预防医学 | 3859篇 |
眼科学 | 720篇 |
药学 | 29945篇 |
37篇 | |
中国医学 | 3774篇 |
肿瘤学 | 4377篇 |
出版年
2024年 | 79篇 |
2023年 | 1037篇 |
2022年 | 1274篇 |
2021年 | 2240篇 |
2020年 | 2414篇 |
2019年 | 2399篇 |
2018年 | 2448篇 |
2017年 | 2771篇 |
2016年 | 2591篇 |
2015年 | 2568篇 |
2014年 | 4399篇 |
2013年 | 7357篇 |
2012年 | 4445篇 |
2011年 | 4559篇 |
2010年 | 3664篇 |
2009年 | 3251篇 |
2008年 | 3051篇 |
2007年 | 3082篇 |
2006年 | 2742篇 |
2005年 | 2529篇 |
2004年 | 2114篇 |
2003年 | 1901篇 |
2002年 | 1459篇 |
2001年 | 1411篇 |
2000年 | 1074篇 |
1999年 | 916篇 |
1998年 | 774篇 |
1997年 | 712篇 |
1996年 | 591篇 |
1995年 | 572篇 |
1994年 | 490篇 |
1993年 | 421篇 |
1992年 | 478篇 |
1991年 | 407篇 |
1990年 | 320篇 |
1989年 | 266篇 |
1988年 | 261篇 |
1987年 | 248篇 |
1986年 | 190篇 |
1985年 | 211篇 |
1984年 | 173篇 |
1983年 | 132篇 |
1982年 | 117篇 |
1981年 | 93篇 |
1980年 | 63篇 |
1979年 | 64篇 |
1978年 | 70篇 |
1977年 | 49篇 |
1976年 | 51篇 |
1975年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
《Value in health》2022,25(11):1821-1827
BackgroundNovel oncology treatment strategies increasingly use medicines with distinct but complementary mechanisms of action in combination or in close sequence. Payers, when confronted with higher total cost of providing combination regimens involving multiple therapies and usually longer treatment durations, are reluctant to reimburse them, particularly when they perceive the expected incremental benefits from adding a new medicine (the add-on) to a currently reimbursed medicine (the backbone) not to represent value for money to the health system. Nevertheless, depending on how value is attributed to the add-on versus the backbone, a clinically effective medicine used as part of a regimen that increases treatment duration might be found “not cost-effective at zero price.” This phenomenon, signaling a policy problem not a pricing issue, first needs to be better understood before a generalizable and transparent solution can be presented.ObjectiveThis article sets out when this policy challenge arises and describes general principles that any proposed solution to the value attribution problem must satisfy.MethodsWe develop a simplified conceptual framework and use this to address 2 topics. The first is to understand the origin of problems posed by the current approach for attributing value in incremental cost-effectiveness analyses of combination regimens. The second is to discuss 2 new approaches in the literature designed to address the challenge.FindingsWe find that neither meets our criteria, meaning that further work is needed to resolve the issue. Finally, we briefly discuss the implications of relaxing the simplifying assumptions in our conceptual framework. 相似文献
32.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
33.
34.
35.
《Journal of the American College of Radiology》2022,19(5):655-662
PurposeTo improve the efficiency and accuracy of clinicians documenting acute clinical events related to contrast agent administration using a web browser–based semistructured documentation support tool.MethodsA new tool called Contrast Incident Support and Reporting (CISaR) was developed to enable radiologists responding to contrast reactions to document inciting contrast class, type of event, severity of contrast reaction, and recommendation for future contrast use. Retrospective analysis was conducted of all CT and MRI examinations performed between February 2018 and December 2019 across our hospital system with associated contrast reaction documentation. Time periods were defined as before tool deployment, early adoption, and steady-state deployment. The primary outcome measure was the presence of event documentation by a radiologist. The secondary outcome measure was completeness of the documentation parameters.ResultsA total of 431 CT and MRI studies with reactions were included in the study, and 50% of studies had radiologist documentation during the pre-CISaR period. This increased to 66% during the early adoption period and 89% in the post-CISaR period. It took approximately 9 months from the introduction of CISaR to reach full adoption and become the main method for adverse contrast reaction documentation. The percentage of radiologist documentation that detailed provoking contrast agent class, severity of reaction, reaction type, and future contrast agent recommendation all significantly increased (P < .0001), with greater than 95% inclusion of each element.ConclusionThe implementation of a semistructured electronic application for adverse contrast reaction reporting significantly increased radiologist documentation rate and completeness of the documentation. 相似文献
36.
《Research in social & administrative pharmacy》2022,18(8):3284-3289
BackgroundAdverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.ObjectivesThis trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12–24 months following hospital discharge.MethodsThe study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.SummaryIt is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge. 相似文献
37.
异质性耐药是一种特殊的细菌耐药类型,常表现为同一克隆来源的不同细菌亚群对某种抗菌药物表现出不一致的耐药特征,大多数亚群对某种抗菌药物敏感,而少部分亚群对其耐药或高度耐药。异质性耐药分离株常会导致特定抗菌药物抗感染治疗失败。针对异质性耐药菌较为深入的研究主要集中于革兰阴性菌,革兰阳性球菌的相关报道较少。近年有研究报道万古霉素、利奈唑胺、苯唑西林等多种类型抗菌药物异质性耐药金黄色葡萄球菌分离株出现,但其实际临床意义尚待进一步评估。此文对金黄色葡萄球菌异质性耐药机制和检测技术最新进展进行综述,为细菌异质性耐药机制研究和新型检测技术研发提供新的思路。 相似文献
38.
[摘要] HIV相关淋巴瘤是常见的HIV相关肿瘤之一,在联合抗反转录病毒治疗(combination antiretroviral therapy, cART)出现之前,其治疗效果极差。在cART时代,HIV相关淋巴瘤的基础及临床研究取得了重大进展,这些为挖掘治疗新靶点提供了依据,使优化HIV相关淋巴瘤的诊治成为可能。本文对近年来HIV相关淋巴瘤的诊断和治疗进展进行综述。 相似文献
39.
Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn’s disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM. 相似文献
40.